Boehringer Ingelheim and OSE Immunotherapeutics to Present Phase 1 Results with First-in-Class SIRPα Inhibitor BI 765063 in Advanced Solid Tumors at ESMO 2021
13 sept. 2021 01h30 HE
|
OSE Immunotherapeutics
BI 765063, a first-in-class SIRPα inhibitor in the SIRPα/CD47 “Don’t eat me” pathway, is being developed under collaborative agreement between OSE Immunotherapeutics and Boehringer Ingelheim. ...
OSE Immunotherapeutics Receives U.S. Patent Notice of Allowance for Tedopi®
07 sept. 2021 01h30 HE
|
OSE Immunotherapeutics
Further Strengthens Global Intellectual Property Portfolio for Tedopi®in Non-Small Cell Lung Cancer until 2035 NANTES, France, Sept. 07, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN:...
OSE Immunotherapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
01 sept. 2021 12h00 HE
|
OSE Immunotherapeutics
NANTES, France, Sept. 01, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173) today announced it will present at the H.C. Wainwright 23rd Annual Global Investment Conference. The...
OSE Immunotherapeutics and ARCAGY-GINECO Announce First Patient Randomized in Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Pembrolizumab in Ovarian Cancer
26 août 2021 12h00 HE
|
OSE Immunotherapeutics
Clinical trial sponsored and conducted by the French oncology cooperative group ARCAGY-GINECO and supported by Merck Sharp & Dohme Corp. (MSD), a subsidiary of Merck & Co., Inc., Kenilworth,...
Servier and OSE Immunotherapeutics Announce Enrollment of First Patient in OSE-127/S95011 Phase 2 Clinical Trial in Sjögren’s Syndrome
25 août 2021 12h00 HE
|
OSE Immunotherapeutics
PARIS and NANTES, France, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Servier, an independent global pharmaceutical group, and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE), a French biotech,...
OSE Immunotherapeutics Announces Upcoming Investor Conferences and R&D Day
24 août 2021 12h00 HE
|
OSE Immunotherapeutics
NANTES, France, Aug. 24, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) today announced that the Company will be present at the following investor events: H.C....
OSE Immunotherapeutics Announces Voluntary Pause of Enrollment in the CoVepiT Phase 1 Study
19 juil. 2021 12h00 HE
|
OSE Immunotherapeutics
NANTES, France, July 19, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) today announced a voluntary and temporary pause of enrollment and dosing in its ongoing...
OSE Immunotherapeutics Receives a €10 Million Payment Corresponding to the First Tranche of the Financing Granted by the European Investment Bank
09 juil. 2021 12h00 HE
|
OSE Immunotherapeutics
This financing will further support the progress and expansion of OSE Immunotherapeutics’ lead clinical development programs in therapeutic areas with high unmet medical needs.This €10 million payment...
OSE Immunotherapeutics Announces Manufacturing Agreement with Cenexi for Clinical Batches of CoVepiT, OSE’s Multi-Target Second-Generation COVID-19 Vaccine
30 juin 2021 01h30 HE
|
OSE Immunotherapeutics
NANTES, France and FONTENAY-SOUS-BOIS, France, June 30, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) and Cenexi, a French contract development and manufacturing...
OSE Immunotherapeutics Reports on its 2021 Virtual Combined General Shareholder’s Meeting
24 juin 2021 12h00 HE
|
OSE Immunotherapeutics
NANTES, France, June 24, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced that all the resolutions submitted to a vote at the Combined General...